Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
FORTIFY, a Phase 1b indication expansion trial of PLN-101095, continues strong enrollment
Covered in this story
Call it yourself
No calls on $PLRX yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Pliant Therapeutics →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.